Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market Size, Share and Analysis by Drug Class (Alpha-1 proteinase inhibitor, Bronchodilators, Steroids, Antibiotics), By Route of Administration (Oral, Injection, Inhalation), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Stores), and Regional Forecast, 2026-2034

The global alpha 1 antitrypsin deficiencytreatment market size was valued at USD 3.22 billion in 2025. The market is projected to grow from USD 3.58 billion in 2026 to USD 8.36 billion by 2034, exhibiting a CAGR of 11.20% during the forecast period. The global alpha-1 antitrypsin deficiency treatment market size expected to drive significant growth by 2026. Alpha-1 antitrypsin is one of the protein synthesised in the liver and travels through the blood protecting the organs of the body from the harmful effects of other proteins. Alpha-1 Antitrypsin Deficiency (AATA), also called genetic Chronic Obstructive Pulmonary Disease (COPD), refers to a genetic condition resulting in increased susceptibility for lung and related disease.

Every individual receives two copies of alpha-1 antitrypsin genes, one form each parent. Individuals that receive one normal and one damaged or two damaged copies of alpha-1 antitrypsin genes have considered to have alpha-1 antitrypsin deficiency. The treatment of alpha-1 antitrypsin deficiency has received huge attention due to the guidelines and recommendations given by the government of different countries. In 2016, the FDA granted expanded label approval to Glassia a drug for alpha-1 antitrypsin deficiency by Kamada Ltd., for self-infusion, enabling patients to self-administer the drug. This is expected to increase the demand for Glassia further augmenting the global alpha-1 antitrypsin deficiency treatment market. 

The growth in global alpha 1 antitrypsin deficiency treatment market size is being driven by the emerging guideline for the treatment and diagnosis of alpha-1 antitrypsin deficiency treatment, potential pipeline products and rising awareness of alpha-1 antitrypsin deficiency. Furthermore, the rising prevalence of alpha-1 antitrypsin deficiency is expected to boost the global alpha-1 antitrypsin deficiency treatment market in the forecast period. 

Request for Customization   to gain extensive market insights.

However, lack of diagnostic methods due to which alpha-1 antitrypsin deficiency remains undetected or sometimes misinterpreted as asthma is a major factor that can hamper the growth in alpha-1 antitrypsin deficiency treatment market. According to the Alpha-1 Foundation, the around 3% of all the people with Chronic Obstructive Pulmonary Disease (COPD) are likely to have undetected alpha-1 antitrypsin deficiency, which can act as a restraining factor in the growth in global alpha-1 antitrypsin deficiency treatment market. 

Key Players Covered 

Some of the major companies that are present in the global alpha 1 antitrypsin deficiency treatment market are Grifols S.A., CSL Limited, Baxter, Kamada Ltd., Takeda Pharmaceutical Company Limited, Abeona Therapeutics Inc., and other players.

SEGMENTATION

The alpha-1 proteinase inhibitor segment is estimated to witness a fast expansion which can be attributed to the new product launch, potential pipeline candidates and increased research on existing products. In August 2015, European Commission granted marketing authorization to Respreeza, a drug for the treatment of alpha-1 antitrypsin deficiency manufactured by CSL Behring in all European union, which is expected to drive the alpha-1 proteinase inhibitor segment. 

Key Insights 

• Prevalence of Alpha-1 Antitrypsin deficiency
• Pipeline analysis
• Patent snapshot
• Regulatory scenario for key countries
• Alpha-1 Antitrypsin deficiency treatment guidelines
• Key mergers and acquisitions

Regional Analysis

The global alpha-1 proteinase inhibitor market has been segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. In North America, the alpha-1 antitrypsin deficiency treatment market is expected to grow during the projected period owing to the recommendations for augmentation therapy for alpha-1 antitrypsin deficiency treatment. The Clinical Practice Guidelines published in the Journal of the COPD Foundation recommends augmentation therapy for all those who have alpha-associated lung diseases. The alpha-1 antitrypsin deficiency treatment market in Europe and Asia Pacific is anticipated to expand in the forecast period owing to the rising prevalence of alpha-1 antitrypsin deficiency. 

Key Industry Developments

• In November 2017, Grifols, S.A., received FDA approval for A1AT Genotyping Test for the diagnosis of alpha-1 antitrypsin deficiency serving as an innovative genetic test which will enable precise and early detection.
• In June 2016, the FDA granted entended label approval to Glassia a drug for alpha-1 antitrypsin deficiency by Kamada Ltd., for self-infusion, enabling patients to self-administer the drug.
• In August 2015, European Commission granted marketing authorization to Respreeza, a drug for the treatment of alpha-1 antitrypsin deficiency manufactured by CSL Behring in all European union.